Shots:
- Genrix Bio has granted Cullinan exclusive global license to velinotamig, excl. Greater China for all indications, with Cullinan planning to develop it in autoimmune diseases
- As per the deal, Genrix will receive $20M upfront, ~$292M in development & regulatory milestones & ~$400M in sales-based milestones, with net sales-based tiered royalties from mid-single digits up to the mid- teens in Cullinan-licensed areas
- Genrix will initiate a P-I trial in Chinese pts with autoimmune disease by 2025 end, with Cullinan leveraging the data to lead global development of velinotamig post-study completion
Ref: GlobeNewswire | Image: Cullinan Therapeutics and Genrix Bio | Press Release
Related News:- Astellas Enters a ~$1.54B Licensing Agreement with Evopoint Biosciences to Develop & Commercialize XNW27011
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
